213 related articles for article (PubMed ID: 14742925)
21. The use of proton MRS in the differential diagnosis of brain tumors and tumor-like processes.
Gajewicz W; Papierz W; Szymczak W; Goraj B
Med Sci Monit; 2003 Sep; 9(9):MT97-105. PubMed ID: 12960934
[TBL] [Abstract][Full Text] [Related]
22. Targeting regions with highest lipid content on MR spectroscopy may improve diagnostic yield in stereotactic biopsy.
Ng WH; Lim T
J Clin Neurosci; 2008 May; 15(5):502-6. PubMed ID: 18334298
[TBL] [Abstract][Full Text] [Related]
23. Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma recurrence from posttreatment effects.
Fink JR; Carr RB; Matsusue E; Iyer RS; Rockhill JK; Haynor DR; Maravilla KR
J Magn Reson Imaging; 2012 Jan; 35(1):56-63. PubMed ID: 22002882
[TBL] [Abstract][Full Text] [Related]
24. Association of 99mTc-MIBI brain SPECT and proton magnetic resonance spectroscopy (1H-MRS) to assess glioma recurrence after radiotherapy.
Palumbo B; Lupattelli M; Pelliccioli GP; Chiarini P; Moschini TO; Palumbo I; Siepi D; Buoncristiani P; Nardi M; Giovenali P; Palumbo R
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):88-93. PubMed ID: 16557208
[TBL] [Abstract][Full Text] [Related]
25. Identification of MRI and 1H MRSI parameters that may predict survival for patients with malignant gliomas.
Li X; Jin H; Lu Y; Oh J; Chang S; Nelson SJ
NMR Biomed; 2004 Feb; 17(1):10-20. PubMed ID: 15011246
[TBL] [Abstract][Full Text] [Related]
26. Metabolic alterations in the peritumoral brain in cases of meningiomas: 1H-MRS study.
Chernov MF; Nakaya K; Kasuya H; Kato K; Ono Y; Yoshida S; Nakamura R; Suzuki T; Muragaki Y; Iseki H; Kubo O; Hori T; Takakura K
J Neurol Sci; 2009 Sep; 284(1-2):168-74. PubMed ID: 19497588
[TBL] [Abstract][Full Text] [Related]
27. Temporal window of metabolic brain vulnerability to concussion: a pilot 1H-magnetic resonance spectroscopic study in concussed athletes--part III.
Vagnozzi R; Signoretti S; Tavazzi B; Floris R; Ludovici A; Marziali S; Tarascio G; Amorini AM; Di Pietro V; Delfini R; Lazzarino G
Neurosurgery; 2008 Jun; 62(6):1286-95; discussion 1295-6. PubMed ID: 18824995
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of cerebral glioma grade by using normal side creatine as an internal reference in multi-voxel 1H-MR spectroscopy.
Yerli H; Ağildere AM; Ozen O; Geyik E; Atalay B; Elhan AH
Diagn Interv Radiol; 2007 Mar; 13(1):3-9. PubMed ID: 17354186
[TBL] [Abstract][Full Text] [Related]
29. In vivo quantification of the metabolites in normal brain and brain tumors by proton MR spectroscopy using water as an internal standard.
Tong Z; Yamaki T; Harada K; Houkin K
Magn Reson Imaging; 2004 Jun; 22(5):735-42. PubMed ID: 15172069
[TBL] [Abstract][Full Text] [Related]
30. Differentiation of intracranial tuberculomas and high grade gliomas using proton MR spectroscopy and diffusion MR imaging.
Peng J; Ouyang Y; Fang WD; Luo TY; Li YM; Lv FJ; Zhang ZW; Li XY
Eur J Radiol; 2012 Dec; 81(12):4057-63. PubMed ID: 22749802
[TBL] [Abstract][Full Text] [Related]
31. [Magnetic resonance proton spectroscopy in neurooncology--preliminary report].
Kubas B; Tarasów E; Dzienis W; Łebkowski W; Zimnoch L; Dziecioł J; Siergiejczyk L; Walecki J; Lewko J
Neurol Neurochir Pol; 2001; 35 Suppl 5():90-100. PubMed ID: 11935688
[TBL] [Abstract][Full Text] [Related]
32. Manually adjusted versus vendor-preset definition of metabolite boundaries impact on proton metabolite ratios.
Petrou M; Sundgren PC; Pang Y; Rohrer S; Foerster B; Chenevert TL
Acad Radiol; 2007 Mar; 14(3):340-3. PubMed ID: 17307667
[TBL] [Abstract][Full Text] [Related]
33. [MR spectroscopy in the differential diagnosis of focal brain lesions in neurofibromatosis type 1 patients].
Alkan A; Kutlu R; Siğirci A; Baysal T; Altinok T; Dusak A; Saraç K
Tani Girisim Radyol; 2003 Jun; 9(2):166-70. PubMed ID: 14661483
[TBL] [Abstract][Full Text] [Related]
34. [Changes in 1H-MRS in glioma patients before and after irradiation: the significance of quantitative analysis of choline-containing compounds].
Isobe T; Matsumura A; Anno I; Nagatomo Y; Yoshizawa T; Itai Y; Nose T
No Shinkei Geka; 2003 Feb; 31(2):167-72. PubMed ID: 12616652
[TBL] [Abstract][Full Text] [Related]
35. Longitudinally monitoring chemotherapy effect of malignant musculoskeletal tumors with in vivo proton magnetic resonance spectroscopy: an initial experience.
Hsieh TJ; Li CW; Chuang HY; Liu GC; Wang CK
J Comput Assist Tomogr; 2008; 32(6):987-94. PubMed ID: 19204465
[TBL] [Abstract][Full Text] [Related]
36. Tissue characterization of glioma by proton magnetic resonance spectroscopy and perfusion-weighted magnetic resonance imaging: glioma grading and histological correlation.
Toyooka M; Kimura H; Uematsu H; Kawamura Y; Takeuchi H; Itoh H
Clin Imaging; 2008; 32(4):251-8. PubMed ID: 18603178
[TBL] [Abstract][Full Text] [Related]
37. Quantitative apparent diffusion coefficients in the characterization of brain tumors and associated peritumoral edema.
Server A; Kulle B; Maehlen J; Josefsen R; Schellhorn T; Kumar T; Langberg CW; Nakstad PH
Acta Radiol; 2009 Jul; 50(6):682-9. PubMed ID: 19449234
[TBL] [Abstract][Full Text] [Related]
38. [Usefulness of Cho/Cr ratio in proton MR spectroscopy for differentiating residual/recurrent glioma from non-neoplastic lesions].
Ando K; Ishikura R; Nagami Y; Morikawa T; Takada Y; Ikeda J; Nakao N; Matsumoto T; Arita N
Nihon Igaku Hoshasen Gakkai Zasshi; 2004 Mar; 64(3):121-6. PubMed ID: 15148787
[TBL] [Abstract][Full Text] [Related]
39. Malignancy assessment of brain tumours with magnetic resonance spectroscopy and dynamic susceptibility contrast MRI.
Fayed N; Dávila J; Medrano J; Olmos S
Eur J Radiol; 2008 Sep; 67(3):427-33. PubMed ID: 18442889
[TBL] [Abstract][Full Text] [Related]
40. Influences of dopaminergic treatment on motor cortex in Parkinson disease: a MRI/MRS study.
Lucetti C; Del Dotto P; Gambaccini G; Ceravolo R; Logi C; Berti C; Rossi G; Bianchi MC; Tosetti M; Murri L; Bonuccelli U
Mov Disord; 2007 Nov; 22(15):2170-5. PubMed ID: 17722082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
